Abstract
Atrial fibrillation (AF) is an established independent risk factor for stroke. Current guidelines regard AF as binary; either present or absent, with the decision for anti-coagulation driven by clinical variables alone. However, there are increasing data to support a biological gradient of AF burden and stroke risk, both in clinical and non-clinical AF phenotypes. As such, this raises the concept of combining AF burden assessment with a clinical risk score to refine and individualize the assessment of stroke risk in AF - the CHA2DS2VASc-AFBurden score. We review the published data supporting a biological gradient to try and construct a putative schema of risk attributable to AF burden.
Original language | English |
---|---|
Pages (from-to) | 665-673 |
Number of pages | 9 |
Journal | EP Europace |
Volume | 23 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 May 2021 |
Externally published | Yes |
Keywords
- Atrial fibrillation
- Atrial high rate episodes
- Burden
- Duration
- Stroke
- Systemic embolism